The Soluble Guanylate Cyclase Stimulator BAY 41-2272 Inhibits Vascular Smooth Muscle Growth through the cAMP-Dependent Protein Kinase and cGMP-Dependent Protein Kinase Pathways
Authors:
- Danielle N. MartinDMDanielle N. Martin
- Jonathan C. FoxJFJonathan C. Fox
- Natalia N. MendelevNMNatalia N. Mendelev
- Trisha A. BrownTBTrisha A. Brown
- David A. TulisDTDavid A. Tulis
- 1 November 2011
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 339 (2) , 394-402
Abstract
Vascular smooth muscle (VSM) proliferation and migration are key components in vessel remodeling. Cyclic nucleotide signaling is protective and has long-served as a therapeutic target against undesired VSM growth. The present work analyzed the effects of the soluble guanylate cyclase (sGC) stimulator 3-(4-amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine [BAY 41-2272 (BAY)] on VSM growth, and we hypothesize that BAY has the capacity to reduce proliferation and migration via cyclic nucleotide-driven kinase signaling. Perivascular BAY postballoon injury reduced neointimal growth by ∼40% compared with vehicle controls after 2 weeks. In VSM cells, BAY (10 μM) reduced proliferation by ∼40% after 72 h and migration by ∼40% after 6 h and ∼60% after 18 h without deleterious effects on cell viability. cGMP content peaked (248×) 20 min after BAY treatment and remained elevated (140×) through 60 min; however, BAY did not affect cAMP levels compared with controls. Conventional and In-Cell Western analyses showed increases in vasodilator-stimulated phosphoprotein (VASP) phosphorylation (pVASP) at serines 239 (3×) and 157 (2×), respective markers of cGMP- and cAMP-directed protein kinases (PKG and PKA, respectively). The PKG inhibitor YGRKKRRQRRRPPLRKKKKKH peptide (DT-2) completely reversed BAY-mediated increases in pVASPSer239 and BAY-mediated inhibition of migration. In comparison, the PKA inhibitor peptide PKI further potentiated BAY-stimulated pVASPSer157 and pVASPSer239 and partially reversed the antiproliferative effects of BAY. This is the first report demonstrating the effectiveness of BAY in reducing neointimal growth with direct evidence for PKG-specific antimigratory and PKA-specific antiproliferative mechanisms. Conclusively, the sGC stimulator BAY reduces VSM growth through cGMP-dependent PKG and PKA processes, providing support for continued evaluation of its clinical utility.Keywords
This publication has 36 references indexed in Scilit:
- PKA and Epac synergistically inhibit smooth muscle cell proliferationJournal of Molecular and Cellular Cardiology, 2011
- Amyloid-β Inhibits No-cGMP Signaling in a CD36- and CD47-Dependent MannerPLOS ONE, 2010
- Heme Oxygenase-1 Deficiency Leads to Alteration of Soluble Guanylate Cyclase Redox RegulationThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Vimentin expression influences flow dependent VASP phosphorylation and regulates cell migration and proliferationBiochemical and Biophysical Research Communications, 2010
- Thrombospondin‐1 is an inhibitor of pharmacological activation of soluble guanylate cyclaseBritish Journal of Pharmacology, 2010
- Antigrowth Properties of BAY 41-2272 in Vascular Smooth Muscle CellsJournal of Cardiovascular Pharmacology, 2009
- YC-1 Stimulates the Expression of Gaseous Monoxide-Generating Enzymes in Vascular Smooth Muscle CellsMolecular Pharmacology, 2009
- Vasodilator-Stimulated Phosphoprotein Regulates Proliferation and Growth Inhibition by Nitric Oxide in Vascular Smooth Muscle CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- YC-1-Mediated Vascular Protection through Inhibition of Smooth Muscle Cell Proliferation and Platelet FunctionBiochemical and Biophysical Research Communications, 2002
- Regulation of the Expression of Cyclic GMP-Dependent Protein Kinase by Cell Density in Vascular Smooth Muscle CellsJournal of Vascular Research, 1994